|
|
Volumn 27, Issue 1, 2009, Pages 108-109
|
|
Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG, Department of Urology, The University of Texas, M. D. Anderson Cancer Center, Houston, TX
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEVACIZUMAB;
SORAFENIB;
SUNITINIB;
CARDIOVASCULAR DISEASE;
CONTROLLED STUDY;
CYTOREDUCTIVE SURGERY;
GASTROINTESTINAL SYMPTOM;
HOSPITAL READMISSION;
HUMAN;
INFECTIOUS COMPLICATION;
KIDNEY CARCINOMA;
KIDNEY SURGERY;
MAJOR CLINICAL STUDY;
METASTASIS;
MOLECULAR THERAPY;
MORBIDITY;
NEPHRECTOMY;
PERIOPERATIVE COMPLICATION;
POSTOPERATIVE COMPLICATION;
PRIORITY JOURNAL;
PROGNOSIS;
RECURRENT CANCER;
SHORT SURVEY;
THROMBOEMBOLISM;
TREATMENT OUTCOME;
TREATMENT RESPONSE;
WOUND COMPLICATION;
|
|
EID: 57849109406
PISSN: 10781439
EISSN: None
Source Type: Journal
DOI: 10.1016/j.urolonc.2008.11.016 Document Type: Short Survey |
|
Times cited : (2)
|
|
References (0)
|